HCW Biologics Files 8-K
Ticker: HCWB · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1828673
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
HCW Biologics filed a standard 8-K, no major news.
AI Summary
HCW Biologics Inc. filed an 8-K on February 3, 2025, to report information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by HCW Biologics Inc. to the SEC, without disclosing any new material events or financial performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information or disclose any significant risks.
Key Players & Entities
- HCW Biologics Inc. (company) — Registrant
- February 03, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 2929 N. Commerce Parkway (address) — Principal Executive Offices
- Miramar, Florida (location) — Principal Executive Offices City and State
FAQ
What is the primary purpose of this 8-K filing for HCW Biologics Inc.?
The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and Financial Statements and Exhibits, as of February 3, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is February 03, 2025.
In which state is HCW Biologics Inc. incorporated?
HCW Biologics Inc. is incorporated in Delaware.
What is the principal executive office address of HCW Biologics Inc.?
The principal executive office address of HCW Biologics Inc. is 2929 N. Commerce Parkway, Miramar, Florida, 33025.
Does this 8-K filing disclose any specific financial results or material events?
No, this 8-K filing does not disclose specific financial results or material events; it serves as a routine reporting document.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-02-03 07:30:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
Filing Documents
- hcwb-20250203.htm (8-K) — 41KB
- hcwb-ex99_1.htm (EX-99.1) — 23KB
- img90053791_0.jpg (GRAPHIC) — 9KB
- 0000950170-25-012021.txt ( ) — 194KB
- hcwb-20250203.xsd (EX-101.SCH) — 24KB
- hcwb-20250203_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 3, 2025, HCW Biologics Inc. (the "Company") issued a press release announcing that the Company was cleared by the U.S. Food and Drug Administration to proceed to evaluate HCW9302, one of the Company's lead product candidates, in a Phase 1 clinical trial in patients with moderate to severe alopecia areata. A copy of that press release is furnished as Exhibit 99.1 hereto. The information furnished in this Current Report, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. 99.1 Press release by HCW Biologics Inc. dated February 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: February 3, 2025 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer